Skip to main content
Premium Trial:

Request an Annual Quote

Unsolicited Bid Causes Applied Imaging to Raise Price Genetix Must Pay for It

NEW YORK (GenomeWeb News) — Applied Imaging today said that an unsolicited bid from a third party to acquire all of its outstanding shares has caused it to the raise by around 24 percent the original price that suitor Genetix will pay to acquire it.
 
Genetix will now pay around $22.7 million for Applied Imaging after the companies amended the terms of the acquisition on Nov. 2 following the unsolicited bid.
 
As GenomeWeb News reported in September, Genetix said it would acquire Applied Imaging for $18.3 million in cash, or $3.06 per share. At the time the companies said the deal would close in the fourth quarter
 
Yesterday’s amendment increased from $3.70 per share to $3.80 the amount Genetix will pay for Applied Imaging's stockholders per share.
 
The firms said they expect to meet on Nov. 21 to approve the proposed acquisition.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.